JP2016505003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505003A5 JP2016505003A5 JP2015549902A JP2015549902A JP2016505003A5 JP 2016505003 A5 JP2016505003 A5 JP 2016505003A5 JP 2015549902 A JP2015549902 A JP 2015549902A JP 2015549902 A JP2015549902 A JP 2015549902A JP 2016505003 A5 JP2016505003 A5 JP 2016505003A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- biological sample
- mammalian
- binding
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 201000011510 cancer Diseases 0.000 claims 30
- 238000000034 method Methods 0.000 claims 30
- 239000012472 biological sample Substances 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 13
- 102000004169 proteins and genes Human genes 0.000 claims 13
- 229960005486 vaccine Drugs 0.000 claims 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 12
- 229960002685 biotin Drugs 0.000 claims 6
- 235000020958 biotin Nutrition 0.000 claims 6
- 239000011616 biotin Substances 0.000 claims 6
- 239000003638 chemical reducing agent Substances 0.000 claims 6
- 239000002563 ionic surfactant Substances 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 5
- 238000001556 precipitation Methods 0.000 claims 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000003495 polar organic solvent Substances 0.000 claims 3
- 239000002244 precipitate Substances 0.000 claims 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108010090804 Streptavidin Proteins 0.000 claims 2
- 230000002152 alkylating effect Effects 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims 2
- 239000002198 insoluble material Substances 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002195 soluble material Substances 0.000 claims 2
- 238000000638 solvent extraction Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims 1
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 claims 1
- 108010087904 neutravidin Proteins 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012905669 | 2012-12-24 | ||
| AU2012905667 | 2012-12-24 | ||
| AU2012905669A AU2012905669A0 (en) | 2012-12-24 | Vaccine booster | |
| AU2012905667A AU2012905667A0 (en) | 2012-12-24 | Vaccines for treatment of cancer | |
| AU2013203806 | 2013-04-11 | ||
| AU2013203806A AU2013203806B2 (en) | 2012-12-24 | 2013-04-11 | Vaccines for the treatment or prevention of cancer |
| AU2013903592 | 2013-09-18 | ||
| AU2013903592A AU2013903592A0 (en) | 2013-09-18 | Vaccines for the treatment or prevention of cancer | |
| PCT/AU2013/001523 WO2014100857A1 (en) | 2012-12-24 | 2013-12-24 | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017162A Division JP2018111695A (ja) | 2012-12-24 | 2018-02-02 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505003A JP2016505003A (ja) | 2016-02-18 |
| JP2016505003A5 true JP2016505003A5 (enExample) | 2017-02-09 |
| JP6286445B2 JP6286445B2 (ja) | 2018-02-28 |
Family
ID=53547734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549902A Expired - Fee Related JP6286445B2 (ja) | 2012-12-24 | 2013-12-24 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
| JP2018017162A Pending JP2018111695A (ja) | 2012-12-24 | 2018-02-02 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018017162A Pending JP2018111695A (ja) | 2012-12-24 | 2018-02-02 | がんの治療のためのワクチン及びワクチン有効性を増強するための組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10357538B2 (enExample) |
| EP (2) | EP3446708A1 (enExample) |
| JP (2) | JP6286445B2 (enExample) |
| AU (1) | AU2013370932B2 (enExample) |
| CA (1) | CA2934958A1 (enExample) |
| NZ (1) | NZ629700A (enExample) |
| WO (1) | WO2014100857A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ629700A (en) * | 2012-12-24 | 2017-01-27 | Cell Ideas Pty Ltd | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
| WO2017136539A1 (en) | 2016-02-04 | 2017-08-10 | Hare Joshua M | Mesenchymal stem cells as vaccine adjuvants and methods for using the same |
| AU2017242899A1 (en) * | 2016-04-01 | 2018-07-05 | Apceth Gmbh & Co. Kg | Mesenchymal stem cells to enhance anti-tumor activity of immunotherapy |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| MY202358A (en) * | 2018-03-19 | 2024-04-24 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62221636A (ja) | 1986-03-20 | 1987-09-29 | Chemo Sero Therapeut Res Inst | Ｂ型肝炎ウイルス抗原蛋白の可溶化方法 |
| US5030621A (en) | 1987-04-23 | 1991-07-09 | Bystryn Jean Claude | Shed melanoma antigen compositions |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6379671B1 (en) | 1996-08-19 | 2002-04-30 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the breast |
| WO1999015199A1 (en) | 1997-09-20 | 1999-04-01 | Osiris Therapeutics, Inc. | Antigen presenting mesenchymal stem cells |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| US7229960B2 (en) * | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
| JP2005531507A (ja) * | 2002-03-02 | 2005-10-20 | ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ストローマ細胞前駆体による抗癌物質の局所的な産生および／または送達方法 |
| US20040258705A1 (en) | 2003-02-28 | 2004-12-23 | Antigenics Inc. | Use of lectins to promote oligomerization of glycoproteins and antigenic molecules |
| AU2003903317A0 (en) | 2003-06-27 | 2003-07-10 | Proteome Systems Intellectual Property Pty Ltd | Method of isolating a protein |
| US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
| WO2005093044A1 (en) | 2004-03-22 | 2005-10-06 | Osiris Therapeutics, Inc. | Mesenchymal stem cells and uses therefor |
| AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
| KR101022401B1 (ko) * | 2005-09-29 | 2011-03-15 | 아주대학교산학협력단 | 자살유전자를 발현하는 중간엽 줄기세포를 포함하는 암치료용 조성물 |
| CN1887296B (zh) * | 2006-07-31 | 2011-05-25 | 南京大学生物制药工程研究中心 | 一种诱导抗肿瘤免疫的方法及其在制药中的应用 |
| US8685728B2 (en) * | 2008-01-31 | 2014-04-01 | Rutgers The State University Of New Jersey | Kit containing stem cells and cytokines for use in attenuating immune responses |
| US8771705B2 (en) * | 2009-07-30 | 2014-07-08 | Healthbanks Biotech Co., Ltd. | Combination of protein vaccine and mesenchymal stem cells for treating cancer |
| WO2011043524A1 (ko) * | 2009-10-08 | 2011-04-14 | 주식회사 알앤엘바이오 | 인간 유래 성체 줄기세포를 함유하는 항암용 조성물 |
| JP2013510582A (ja) * | 2009-11-12 | 2013-03-28 | ザ テキサス エーアンドエム ユニバーシティー システム | 間葉幹細胞の球状集合体 |
| KR20120132183A (ko) * | 2011-05-27 | 2012-12-05 | 포항공과대학교 산학협력단 | 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신 |
| DK2744892T3 (en) | 2011-09-23 | 2019-04-23 | Cell Ideas Pty Ltd | THERAPEUTICS USING FAT CELLS AND CELL SECRETIONS |
| NZ629700A (en) * | 2012-12-24 | 2017-01-27 | Cell Ideas Pty Ltd | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
-
2013
- 2013-12-24 NZ NZ629700A patent/NZ629700A/en not_active IP Right Cessation
- 2013-12-24 US US14/655,088 patent/US10357538B2/en not_active Expired - Fee Related
- 2013-12-24 CA CA2934958A patent/CA2934958A1/en not_active Abandoned
- 2013-12-24 EP EP18182531.6A patent/EP3446708A1/en not_active Withdrawn
- 2013-12-24 AU AU2013370932A patent/AU2013370932B2/en not_active Ceased
- 2013-12-24 JP JP2015549902A patent/JP6286445B2/ja not_active Expired - Fee Related
- 2013-12-24 EP EP13867300.9A patent/EP2934578B1/en not_active Not-in-force
- 2013-12-24 WO PCT/AU2013/001523 patent/WO2014100857A1/en not_active Ceased
-
2018
- 2018-02-02 JP JP2018017162A patent/JP2018111695A/ja active Pending
-
2019
- 2019-06-12 US US16/438,703 patent/US20190358291A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016505003A5 (enExample) | ||
| Acunzo et al. | TCTP as therapeutic target in cancers | |
| Jeon et al. | Side-effect test of sorafenib using 3-D skin equivalent based on microfluidic skin-on-a-chip | |
| Ito et al. | Contrasting intra-and extracellular distribution of catalytic ferrous iron in ovalbumin-induced peritonitis | |
| Van de Steen et al. | Bioengineering bacterial encapsulin nanocompartments as targeted drug delivery system | |
| Olsen et al. | Manipulation of cellular spheroid composition and the effects on vascular tissue fusion | |
| Herrera-Rincon et al. | Brief local application of progesterone via a wearable bioreactor induces long-term regenerative response in adult Xenopus hindlimb | |
| Del Turco et al. | Cytocompatibility evaluation of glycol-chitosan coated boron nitride nanotubes in human endothelial cells | |
| Pinto et al. | Cytotoxicity, genotoxicity, transplacental transfer and tissue disposition in pregnant rats mediated by nanoparticles: the case of magnetic core mesoporous silica nanoparticles | |
| JP2017527260A5 (enExample) | ||
| Thakur et al. | Expression and localization of heat-shock proteins during skeletal muscle cell proliferation and differentiation and the impact of heat stress | |
| BR112016007592A2 (pt) | proteína de ligação biespecífica que se liga a pelo menos dois alvos, conjugado de proteína de ligação biespecífica, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, método para produzir uma proteína de ligação biespecífica, método para determinar a reatividade de um paciente a um agente terapêutico que tem capacidade para modular a atividade de um tlr, método para ativar ou inibir células responsivas a tlr9, método para tratar um paciente que precisa de ativação de tlr9 ou inibição de tlr e método para identificar um inibidor ou estimulador de sinalização de tlr | |
| Roy et al. | Attenuation of cadmium-induced vascular toxicity by pro-angiogenic nanorods | |
| Samyesudhas et al. | Differential expression of ARID3B in normal adult tissue and carcinomas | |
| Nightingale et al. | The migrating gubernaculum grows like a “limb bud” | |
| Paquet et al. | Tissue engineering of skin and cornea: Development of new models for in vitro studies | |
| Chen et al. | Redox disruption using electroactive liposome coated gold nanoparticles for cancer therapy | |
| Tao et al. | Layered Double Hydroxide LDH-Loaded miR-141–3p Targets RAB10 Suppressing Cellular Autophagy to Reverse Paclitaxel Resistance in Breast Cancer | |
| Li et al. | Platelet membrane biomimetic nanomedicine induces dual glutathione consumption for enhancing cancer radioimmunotherapy | |
| Su et al. | Novel in situ biosynthesized fluorescent zinc nanoclusters for specific cellular bio-imaging | |
| Zhu et al. | Comparison study of bone defect healing effect of raw and processed pyritum in rats | |
| Degrelle et al. | Iodide transporters expression in early human invasive trophoblast | |
| Altundag et al. | The role of HSP90 in Quercetin-induced apoptosis in human papillary thyroid (B-CPAP) cancer cells | |
| Raza et al. | CD73 and cN-II regulate the cellular response to chemotherapeutic and hypoxic stress in lung adenocarcinoma cells | |
| Parvathy et al. | Unveiling the Symphony of Small Molecules in Cutaneous Harmony, Pathophysiology, Regeneration and Cancer |